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Matrix metalloproteinases (MMPs) are involved in the pathophysiology of several central nervous system diseases 
that share common pathogeneses, such as disruption of the blood-brain barrier (BBB), neuroinflammation, oxidative 
stress, and remodeling of the extracellular matrix (ECM). In early ischemic injury, MMPs participate in disruption of 
the BBB by digesting the basal lamina of capillaries and ECM, leading to vasogenic edema and hemorrhagic 
transformation. However, ECM degradation and remodeling are essential for tissue recovery, with MMPs having a key 
role as modulators of homeostasis between neuronal death and tissue regeneration. Thus, MMPs may be a 
double-edged sword that has a deleterious or beneficial role depending on the stage of brain injury. 
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INTRODUCTION
Extracellular proteases comprise serine proteases, 
tissue-type and urokinase-type plasminogen activator 
(PA), and the families of matrix metalloproteinases 
(MMPs). MMPs are families of enzymes that require a 
zinc ion for catalytic activity. The role of MMPs has 
classically been described as strict regulators of extra-
cellular matrix (ECM) remodeling in tissue morphogene-
sis and wound healing. MMPs regulate cellular activity 
in various ways, including ECM degradation, cell 
adhesion, proteolytic release of ECM-sequestrated mole-
cules, and shedding of cell surface proteins that transduce 
signals from the extracellular environment (Table 1).
1,2 
Recently, a deleterious role of MMPs in several diseases 
of the nervous system has been widely studied. How-
ever, some beneficial functions of MMPs during the 
recovery phase after brain injury have also been sug-
gested. This review focuses on the role of MMPs in the 
acute and recovery phases of cerebral ischemia.
STRUCTURE AND EXPRESSION OF MMPs
According to the basic protein domain and substrate 
preference, there are five major classes of MMPs: 
matrilysins, membrane-type MMPs (MT-MMPs), stro-
melysins, gelatinases, and other recently discovered 
MMP families.
3 The protein structures of MMPs share a 
basic common pattern (Fig. 1) of propeptide and catalytic 
domains. However, they differ in more specific domains. 
The matrilysin MMP-7 has the simplest domain struc-
ture, with the propeptide domain and zinc containing 
catalytic domain, but it degrades most ECM compo-
nents. The MT-MMPs (MMP-14, -15, and -16) have an Journal of Clinical Neurology: Vol. 2, No. 3, 2006
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Figure 1. MMP families.
Beneficial effects Deleterious effects
Cell-fate specification Tumorigenesis
Angiogenesis Disruption of blood-brain barrier
Myelinogenesis Inflammation
Survival of cells Demyelination
Axonal growth Neuronal death
Signaling
Repair processes
Migration of neuronal precursors
Termination of inflammation
Table 1. Effects of MMPs in the central nervous system
additional transmembrane domain, whereas the strome-
lysins (MMP-1, -3, and -10) have a hemopexin domain. 
The gelatinases (MMP-2 and -9) have a unique fibronectin- 
binding domain, allowing them to bind to basement 
membranes. Thus, gelatinases specifically attack type IV 
collagen, laminin, and fibronectin. The common propep-
tide domain maintains the latency state of the enzyme, 
with removal of the signal peptide of this domain 
activating enzymes. Activation can also occur through a 
change in configuration. Proteolytic removal or recon-
figuration of the propeptide domain activates the 
enzymes. Exposure of the catalytic site is referred to as 
the “cysteine switch”.
4 The various MMPs exist as secreted 
or membrane-bound enzymes that require conversion 
from zymogen to active forms through proteolytic 
processing, thus ensuring that MMP expression is tightly 
regulated at the transcriptional and posttranslational 
levels. Additionally, MMPs are also regulated extra-
cellularly by proteins known as tissue inhibitors of 
metalloproteinases (TIMPs).
5 The strict control of the 
activity of MMPs at multiple levels, such as transcrip-
tion, posttranslational modification, and interaction with 
TIMPs is important, because MMPs play sophisticated 
roles and are extremely deleterious if they are erroneously 
activated.
INCREASED MMPs IN EXPERIMENTAL 
CEREBRAL ISCHEMIA
Recent studies have revealed the involvement of 
MMPs with clinical vascular diseases (Table 2). Ischemic 
stroke is often associated with disruption of the blood- 
brain barrier (BBB), leading to vasogenic edema and 
hemorrhage. Numerous animal studies suggest that 
disruption of the BBB and hemorrhagic transformation 
in ischemic stroke results from MMP activation in 
pathologic conditions.
6-9 A deleterious role of MMPs 
associated with BBB injury has been demonstrated by a 
reduced infarct size and less BBB damage after focal 
ischemia in MMP-9 knockout mice,
7,9 and by both MMP 
activation and BBB injury being reduced in mice with 
superoxide dismutase overexpression.
10 In nonhuman 
primates, early opening of the BBB after ischemic stroke 
correlates with elevated MMP-2, whereas hemorrhagic 
transformation is associated with elevated MMP-9.
11,12Kim HY and Han SH. Matrix Metalloproteinases in Cerebral Ischemia 
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Disease Target MMP Specimen Reference
Carotid atherosclerosis MMP-1,2,3,9, TIMP-1,2
MMP-1
MMP-2,9, TIMP-1
MMP-2,8,9
MMP-2, TIMP-1,2
MMP-1,10
MMP-9
Atherosclerotic plaque
Atherosclerotic plaque
Atherosclerotic plaque, serum
Plasma
Serum
Atherosclerotic plaque
Atherosclerotic plaque
Galis et al.
47
Nikkari et al.
48
Tziakas et al.
49
Turu et al.
50
Pawlak et al.
51
Montero et al.
52
Sigala et al.
53
Ischemic heart disease MMP-9
MMP-2,3,9
MMP-2,9
MMP-3
Serum
Plasma
Plasma
Serum
Renko et al.
54
Wu et al.
55
Zeng et al.
56
Samnegard et al.
57
Cerebral ischemia MMP-2,9
MMP-9
MMP-2,9
MMP-9
Plasma
Plasma
Plasma
Brain tissue
Montaner et al.
15
Castellanos et al.
19
Montaner et al.
17
Rosell et al.
18
Intracranial hemorrhage MMP-9
MMP-2,9
MMP-9
MMP-2,3,9, TIMP-1,2
Plasma
Plasma
Brain tissue
Plasma
Castellanos et al.
19
Montaner et al.
17
Rosell et al.
18
Alvarez-Sabin et al.
58
Intracranial aneurysm MMP-9, TIMP
MMP-2,9
MMP-9
Plasma
Serum
Serum
Kim et al.
59
Todor et al.
60
McGirt et al.
61
Vascular dementia MMP-9
MMP-2,3,9
MMP-2,9
Brain tissue
Srain tissue
Cerebrospinal fluid 
Asahina et al.
62
Rosenberg et al.
42
Adair et al.
44
Alzheimer’s disease MMP-1
MMP-3
MMP-9
MMP-2,9, TIMP-1,2
MMP-9, TIMP-1
Brain tissue
Brain tissue
Brain tissue
Plasma
Plasma
Leake et al.
63
Yoshiyama et al.
64
Asahina et al.
62
Lorenzl et al.
46
Inspector et al.
65
Table 2. Clinical vascular diseases, target MMPs, and specimens in various studies
CLINICAL IMPLICATION OF MMPs IN 
ISCHEMIC STROKE
Gelatin zymography has been used to compare MMP 
activity between infarcted and matched noninfarcted 
cerebral tissue of acute or chronic ischemic stroke 
patients.
13 MMP-9 activity was markedly elevated in the 
acute ischemic stroke tissue, whereas increases in 
MMP-2 activity were subtle at 2~5 days after ischemic 
stroke.
13 An association between elevated MMPs and 
BBB disruption is also supported by the significant 
correlation between the level of MMP-9 and stroke 
severity being observed in stroke patients.
14,15 The MMP-9 
levels measured by ELISA after acute cardioembolic 
stroke and the final NIHSS score are closely related,
15 
and MMP-9 appears also to be especially associated 
with hemorrhagic transformation.
16-18 One shortcoming 
of analyzing the correlation between biomarkers and the 
clinicoradiologic outcome is the uncertainty of the cause- Journal of Clinical Neurology: Vol. 2, No. 3, 2006
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and-effect relationship. An increase in plasma MMP-9 
levels may result from an acute-phase reaction or prior 
systemic causes. However, some studies have found that 
high plasma MMP-9 levels were related to hemorrhagic 
transformation, because increased MMP-9 levels were 
detected on admission in patients who subsequently 
developed hemorrhagic transformation in whom the 
initial stroke severity and final infarct volume were 
similar to those without hemorrhagic transformation.
16,19 
Interestingly, a correlation between the baseline MMP-9 
level and hemorrhagic complications after thrombolysis 
treatment has been observed, with the baseline MMP-9 
level being a possible predictor of hemorrhagic compli-
cations after tPA thrombolysis.
17 Measurement of the 
pretreatment level of MMP-9 was suggested as a pos-
sible safety measure when selecting candidates for 
thrombolysis. These data suggest a role for MMP-2 and 
MMP-9 in both the acute and chronic states of cerebral 
ischemia, BBB disruption, and efficacy and complication 
rate of tPA treatment. Future studies should focus on the 
temporal profiles of activation, selective activation 
among MMPs families, and the source of released 
MMPs.
tPA TREATMENT AND THE PA AXIS
PA and MMPs are the major proteases that modulate 
the ECM in the brain. Emerging data show important 
linkages between tPA, MMPs, vasogenic edema, and 
hemorrhage after stroke. Thrombolysis using tPA is the 
only FDA-approved treatment modality in acute stroke 
patients. The beneficial effect of tPA is intravascular 
thrombolysis restoring the blood flow to the ischemic 
parenchymal tissue. However, when tPA gains access to 
the extravascular neural parenchyma through a compro-
mised BBB, any interaction between the NMDA 
receptors and exogenous tPA is a potential threat to the 
neural parenchyma. In addition to the direct neuro-
toxicity of tPA,
20,21 vasogenic edema or parenchymal 
hemorrhage induced by BBB disruption is another 
deleterious complication. MMP-9 may attack compo-
nents of the basal lamina of cerebral vessels, and its 
activation can cause neurovascular damage of the BBB, 
leading to edema and hemorrhagic complications.
6,22,23 
The increased risk of edema and hemorrhagic compli-
cations in stroke patients following tPA therapy may 
therefore be due to tPA-induced upregulation of MMP-9. 
Plasmin is a potent protease that cleaves blood fibrin 
and activates other proteases, and thus is implicated in 
neurovascular and ECM degradation. Plasmin has an 
important role in the mechanism of tPA-induced 
hemorrhage by activating MMP-9 and MMP-2.
24,25 Whilst 
tPA can resolve intravascular blood clots, it can also 
produce abnormally high levels of plasmin that can 
trigger excessive activation of MMPs, leading to uncon-
trollable BBB disruption and, finally, intracranial 
hemorrhagic complications. MMP-9 levels are increased 
by tPA after experimentally induced focal ischemic 
stroke,
26,27 and MMP inhibitors reduce tPA-induced 
hemorrhagic transformation.
27,28 These data suggest that 
the activation of MMP-9 by administered tPA induces 
ischemic injury in the neurovascular unit. Therefore, 
modulating tPA and MMP-9 activity may provide a new 
approach for reducing complications of tPA throm-
bolysis. Once the clinical effects of MMPs are deter-
mined, clinical trials to modulate their activity could be 
started. Coadministration of MMP inhibitor or TIMPs 
with thrombolytic agents could avoid BBB disruption or 
ECM degradation. However, in clinical settings, such a 
drug should be highly tissue specific and avoid disturb-
ing the physiologic ECM-rebuilding properties. Simple 
downregulation of MMP levels could evoke other side 
effects. Many MMP inhibitors have been tested for their 
efficacy in preventing cancer and rheumatoid arthritis,
29,30 
but their side effects have so far precluded clinical trials. 
Thus, balanced modulation of MMP represents the major 
challenge for future stroke therapies.
MMPs IN STROKE RECOVERY
MMPs are known to be rapidly upregulated at 24~48 
hours after ischemia,
12,25,31 but little is known about their 
role during the subsequent recovery phase. The mecha-
nism of stroke recovery mainly involves neuronal 
plasticity, neurogenesis, and angiogenesis.
32,33 MMPs 
may be critical for this recovery process because they Kim HY and Han SH. Matrix Metalloproteinases in Cerebral Ischemia 
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can remodel components of the ECM. MMPs participate 
in dendritic and axonal extension as well as blood vessel 
formation.
34 A recent study showed a beneficial role of 
MMP-9 in the recovery phase of experimental stroke,
35 
with surrogate markers of neuronal plasticity and 
vascular remodeling being correlated with MMP-9 
signals in neurons and astrocytes in the peri-infarction 
area. Delayed inhibition of MMPs at 7 days poststroke 
worsened outcomes at 14 days by decreasing neuro-
vascular remodeling, increasing infarction volumes, and 
blunting behavioral recovery.
35 MMPs may in fact play 
beneficial roles during delayed stroke recovery, despite 
their deleterious effects in the acute phase of stroke. 
MMPs, and in particular MMP-9, have emerged as a 
target for stroke therapy in recent years.
36 Pathophysio-
logic data from cell and animal models have been 
increasingly validated by the correlations between 
MMP-9 biomarkers and clinical outcomes in patients.
16,17 
Therefore, there is growing momentum toward the 
development of MMP inhibitors for stroke therapy. In 
contrast to the therapeutic potential of MMP inhibition 
for acute stroke therapy, approaches to modulating or 
even enhancing MMPs in the late stages of stroke may 
represent novel techniques for improving stroke recovery 
and enhancing the long-term functional outcome. 
However, future studies should focus on how to 
modulate such a delicate and orchestrated role of MMPs 
according to the different phases of stroke. 
MMPs IN SUBCORTICAL ISCHEMIC 
VASCULAR DEMENTIA
The significance of the white matter lesions that 
appear in various neurodegenerative diseases is still 
debated. The pathophysiology of subcortical ischemic 
vascular dementia or CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) is significantly associated with 
white matter lesions.
37-40 Demyelination around affected 
subcortical blood vessels, activated microglia, and macro-
phages can also be found in white matter lesions.
38,41 
Brain tissue in patients with vascular dementia show 
fibrosis of small blood vessels with adjacent demyelina-
tion. Increased levels of several MMPs have also been 
observed in some patients with vascular dementia, with 
MMP-3 observed in reactive astrocytes and microglial 
cells.
42 After controlling for the variation of MMP 
expression with age,
43 the level of active MMP-9 in the 
cerebrospinal fluid or plasma of patients with vascular 
dementia still varies from that in Alzheimer’s disease 
and other neurodegenerative conditions.
44-46 MMPs may 
play an important role in nearly all kinds of dementia, 
especially in vascular dementia, but whether they are 
more important for the disease progress or are only an 
epiphenomenon of tissue adjustment is not clear. The 
profile of MMPs may in the future be a helpful marker 
for differentiating between subtypes of dementia.
CONCLUSIONS
MMPs are implicated in all cerebrovascular diseases 
and play a deleterious role in the pathophysiology of 
BBB disruption, neuroinflammation, oxidative stress, and 
delayed neuronal cell death. MMPs also have a role in 
the subacute or recovery phase through glial scarring, 
neuronal cell migration, and brain tissue recovery. 
Therapeutic strategies designed to modulate the activity 
of MMPs should consider these pleiotropic roles, and 
hence oversimplified experimental approaches with 
MMP inhibitors are likely to produce disappointing 
results. Carefully considering the various effects of 
MMPs is a challenge for future studies.
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